Risk group | Definition | Phase 1 Dec 14, 2015–Mar 20, 2016 | Phase 2 Mar 21, 2016–Nov 13, 2016 | Phase 3 Nov 14, 2016–Feb 5, 2017 | |||
---|---|---|---|---|---|---|---|
Identification strategy | Contact precautions | Identification strategy | Contact precautions | Identification strategy | Contactprecautions | ||
VRE carrier | Patient infected or colonised with VREfm | N/A | Yesa | N/A | Yesa | N/A | Yesa |
VRE suspected | All patients with prior hospitalisation in the ADRZ hospital location Goes from September 1, 2014 until start of zero transmission period | Single rectal swab on admission | Yes, while awaiting result of single admission screening | Single rectal swab on admission | No | Single rectal swab on admission | No |
Patients transferred from nursing homes or rehabilitation centres | Single rectal swab on admission | Yes, while awaiting result of single admission screening | Single rectal swab on admission | No | No | No | |
Roommate of unexpected VRE carrier | N/A | Yesc | 3 separate rectal cultures (collection at day 3, 5 and 7 after the last exposure) | Yesa | 3 separate rectal cultures (collection at day 3, 5 and 7 after the last exposure) | Yesa | |
All patients (incl. low risk) | Hospital wide surveillance | Weekly screening of all patients hospitalised > 2 daysb | N/A | Weekly screening of all patients hospitalised > 2 days | N/A | Monthly screening of all patients hospitalised > 2 days | N/A |